Nvidia and AMD to pay 15% of China chip sale revenues to US government, FT reports

Nvidia and AMD have reportedly agreed to remit 15% of their China chip sales revenues to the U.S. government as a condition for obtaining export licenses for semiconductors, according to a Financial Times report not yet verified by Reuters. This arrangement, initiated under the Trump administration, imposes a significant financial obligation on these companies' China operations and underscores the U.S. government's increasing leverage over critical technology exports.

Analysis

According to a Financial Times report, Nvidia (NVDA) and Advanced Micro Devices (AMD) have reportedly agreed to a significant financial arrangement with the U.S. government, requiring them to remit 15% of revenues from chip sales in China. This payment is stipulated as a condition for obtaining the necessary export licenses, a policy said to have originated under the Trump administration. A 15% levy on top-line revenue, rather than profit, represents a substantial and direct compression of gross margins for both companies on their sales into the critical Chinese market. This development, which carries a mildly negative sentiment for both tickers, underscores the increasing use of export controls as a tool of U.S. trade policy. It is crucial to note that the report has not yet been independently verified by Reuters, introducing a key element of uncertainty for investors evaluating the tangible impact on future earnings.

Key Decisions for Investors

• Investors should prioritize monitoring for official confirmation of this policy from either the companies or U.S. government sources, as the unverified nature of the report is the most critical variable.
• If confirmed, financial models for both Nvidia and AMD must be immediately revised to account for a 15% reduction on China-derived revenue, which would materially impact profitability forecasts and valuation targets.
• This situation elevates the geopolitical risk profile for semiconductor firms with significant China exposure, warranting a potential re-evaluation of position sizing until the terms and finality of this licensing cost are clarified.